Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12078
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorFurumoto, Shozo-
dc.contributor.authorFodero-Tavoletti, Michelle T-
dc.contributor.authorMulligan, Rachel S-
dc.contributor.authorHodges, John-
dc.contributor.authorHarada, Ryuichi-
dc.contributor.authorYates, Paul-
dc.contributor.authorPiguet, Olivier-
dc.contributor.authorPejoska, Svetlana-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorYanai, Kazuhiko-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorKudo, Yukitsuka-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorOkamura, Nobuyuki-
dc.date.accessioned2015-05-16T01:43:28Z
dc.date.available2015-05-16T01:43:28Z
dc.date.issued2014-02-11-
dc.identifier.citationEuropean Journal of Nuclear Medicine and Molecular Imaging 2014; 41(5): 816-26en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12078en
dc.description.abstractDiagnosis of tauopathies such as Alzheimer's disease (AD) still relies on post-mortem examination of the human brain. A non-invasive method of determining brain tau burden in vivo would allow a better understanding of the pathophysiology of tauopathies. The purpose of the study was to evaluate (18)F-THK523 as a potential tau imaging tracer.Ten healthy elderly controls, three semantic dementia (SD) and ten AD patients underwent neuropsychological examination, MRI as well as (18)F-THK523 and (11)C-Pittsburgh compound B (PIB) positron emission tomography (PET) scans. Composite memory and non-memory scores, global and hippocampal brain volume, and partial volume-corrected tissue ratios for (18)F-THK523 and (11)C-PIB were estimated for all participants. Correlational analyses were performed between global and regional (18)F-THK523, (11)C-PIB, cognition and brain volumetrics.(18)F-THK523 presented with fast reversible kinetics. Significantly higher (18)F-THK523 retention was observed in the temporal, parietal, orbitofrontal and hippocampi of AD patients when compared to healthy controls and SD patients. White matter retention was significantly higher than grey matter retention in all participants. The pattern of cortical (18)F-THK523 retention did not correlate with Aβ distribution as assessed by (11)C-PIB and followed the known distribution of tau in the AD brain, being higher in temporal and parietal areas than in the frontal region. Unlike (11)C-PIB, hippocampal (18)F-THK523 retention was correlated with several cognitive parameters and with hippocampal atrophy.(18)F-THK523 does not bind to Aβ in vivo, while following the known distribution of paired helical filaments (PHF)-tau in the brain. Significantly higher cortical (18)F-THK523 retention in AD patients as well as the association of hippocampal (18)F-THK523 retention with cognitive parameters and hippocampal volume suggests (18)F-THK523 selectively binds to tau in AD patients. Unfortunately, the very high (18)F-THK523 retention in white matter precludes simple visual inspection of the images, preventing its use in research or clinical settings.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAlzheimer Disease.radionuclide imagingen
dc.subject.otherAmyloid beta-Peptides.metabolismen
dc.subject.otherAniline Compounds.diagnostic use.pharmacokineticsen
dc.subject.otherBrain.radionuclide imagingen
dc.subject.otherCase-Control Studiesen
dc.subject.otherFemaleen
dc.subject.otherFrontotemporal Dementia.radionuclide imagingen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherProtein Bindingen
dc.subject.otherQuinolines.diagnostic use.pharmacokineticsen
dc.subject.otherRadiopharmaceuticals.diagnostic use.pharmacokineticsen
dc.subject.otherThiazoles.diagnostic use.pharmacokineticsen
dc.subject.otherTissue Distributionen
dc.subject.othertau Proteins.metabolismen
dc.titleIn vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean journal of nuclear medicine and molecular imagingen
dc.identifier.affiliationCentre for PET, Austin Health, Melbourne, Australia,en
dc.identifier.doi10.1007/s00259-013-2681-7en
dc.description.pages816-26en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24514874en
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherDoré, Vincent
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
24514874.pdf70.28 kBAdobe PDFView/Open
Show simple item record

Page view(s)

38
checked on Mar 28, 2024

Download(s)

66
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.